Japanese Encephalitis Vaccine
Brand names: Ixiaro · Active ingredient: Japanese Encephalitis Virus Strain Sa 14-14-2 Antigen (Formaldehyde Inactivated)
In short: IXIARO is a vaccine indicated for the prevention of disease caused by Japanese encephalitis virus (JEV). IXIARO is approved for use in individuals 2 months of age and older.
What is Japanese Encephalitis Vaccine used for?
IXIARO is a vaccine indicated for the prevention of disease caused by Japanese encephalitis virus (JEV). IXIARO is approved for use in individuals 2 months of age and older.
Japanese Encephalitis Vaccine dosage
For intramuscular administration only.
Primary Series:Children 2 months to <3 years of age: Primary immunization with IXIARO consists of two (2) 0.25 mL doses, administered 28 days apart.Individuals 3 years of age and older: Primary immunization with IXIARO consists of two (2) 0.5 mL doses, administered 28 days apart.Complete the primary immunization series at least 1 week prior to potential exposure to JEV.
Booster Dose:Individuals 17 years of age and older: If the primary series of two doses was completed more than 1 year previously, a booster dose may be given if ongoing exposure or re-exposure to JEV is expected.Infants, children and adolescents 2 months to <17 years of age: The safety and immunogenicity of a booster dose has not been evaluated.
IXIARO is administered intramuscularly. The preferred sites for intramuscular injection are the anterolateral aspect of the thigh in infants 2 to 11 months of age, the anterolateral aspect of the thigh (or the deltoid muscle if muscle mass is adequate) in children 1 to <3 years of age, or the deltoid muscle in individuals 3 years of age and older.Do not administer intravenously, intradermally, or subcutaneously.
Prior to agitation, IXIARO is a clear liquid with a white precipitate. Before administration, shake the syringe well to obtain a white, opaque, homogeneous suspension.Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration. If either of these conditions exists, do not administer.Preparation of a 0.25 mL Dose of IXIARO for Administration to Children 2 Months to <3 Years of Age:1. Shake the pre-filled syringe containing 0.5 mL to obtain a homogeneous suspension.2. Remove the syringe tip cap by gently twisting it. Do not attempt to snap or pull the tip off as this may damage the syringe.3. Attach a sterile safety needle to the pre-filled syringe (needle is not provided with IXIARO).4. Hold the syringe in an upright position and uncap the needle.5. Push the plunger stopper up to the edge of the red line on the syringe barrel, indicated by a red arrow *, and discard expelled volume into a medical waste container.6. Lock the needle safety shield and remove the needle.7. Attach a new sterile needle prior to injection of the remaining volume.*If the plunger stopper is pushed beyond the red line, do not administer the vaccine. Repeat the procedure using a new pre-filled syringe.
Preparation of a 0.5 mL Dose of IXIARO for Administration to Individuals 3 Years of Age and Above:1. Shake the pre-filled syringe containing 0.5 mL to obtain a homogeneous suspension.2. Remove the syringe tip cap by gently twisting it. Do not attempt to snap or pull the tip off as this may damage the syringe.3. …
How to take Japanese Encephalitis Vaccine — instructions & advice from the label
Question the vaccine recipient about reactions to previous vaccines, and inform the vaccine recipient of the benefits and risks of IXIARO.Consult current U.S. and international advisories regarding prevalence of Japanese encephalitis in specific locations. Advise the parent, guardian, or recipient that IXIARO may not fully protect everyone who gets the vaccine and that personal precautions should be taken to reduce exposure to mosquito bites (adequate clothing, use of repellents, mosquito nets).Give the parent, guardian, or recipient the Vaccine Information Statements, which are required by the National Childhood Vaccine Injury Act of 1986 to be given prior to immunization, and inquire about previous reactions to vaccines.
Inform the parent, guardian, or recipient of the importance of completing the immunization series.
Instruct the parent, guardian, or recipient to immediately report any signs and/or symptoms of a severe adverse reaction, including anaphylaxis (difficulty breathing, wheezing, weakness or fast heart beat, hives). …
Warnings & precautions
Do not take this medicine if: Severe allergic reaction (e.g., anaphylaxis) after a previous dose of IXIARO, any other Japanese Encephalitis Virus vaccine, or any component of IXIARO, including protamine sulfate, is a contraindication to administration of IXIARO . Alternatively, because of uncertainty as to which component of the vaccine may be responsible, individuals with a history of severe allergic reaction to another Japanese Encephalitis vaccine may be referred to an allergist for evaluation if immunization with IXIARO is considered.
IXIARO contains protamine sulfate, a compound known to cause hypersensitivity reactions in some individuals .
Appropriate medical care should be readily available in case of anaphylactic reaction.
Vaccination with IXIARO may not protect all individuals.
Immunocompromised individuals may have a diminished immune response to IXIARO.
Japanese Encephalitis Vaccine side effects
In infants 2 months to <1 year of age, the most common injection site reaction was redness (>15%); the most common solicited systemic adverse reactions were fever (>20%), irritability (>15%) and diarrhea (>10%). In children 1 to <3 years of age, the most common solicited systemic adverse reaction was fever (>20%). In children 3 to <12 years of age, the most common solicited systemic adverse reaction was fever (>10%). In adolescents 12 to <18 years of age, the most common solicited injection site reactions were pain (15%) and tenderness (10%). In adults 18 years of age and older, the most common injection site reactions were pain (>25%) and tenderness (>25%); the most common solicited systemic adverse reactions were headache (>20%) and myalgia (>10%).
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a vaccine cannot be directly compared to rates in the clinical trials of another vaccine and may not reflect the rates observed in practice.
Clinical Studies in Children 2 Months to <18 Years of Age:
Adverse Events in a Pediatric Trial Comparing IXIARO to U.S.-Licensed Control Vaccines HAVRIX and PREVNAR:
The safety of IXIARO was evaluated in a randomized, controlled, open-label clinical trial in healthy male and female subjects 2 months to <18 years of age, conducted in the Philippines, a country where Japanese Encephalitis is endemic (Study 1)1. …
Drug interactions
In one clinical trial6 in adults, IXIARO was administered concomitantly with HAVRIX (Hepatitis A Vaccine) . In this trial, there was no evidence for interference with the immune response to IXIARO or to HAVRIX when HAVRIX was administered concomitantly with dose 1 of IXIARO . Data are not available on concomitant administration of IXIARO with other US-licensed vaccines.
When IXIARO is administered concomitantly with injectable vaccines, they should be given with separate syringes at different injection sites. IXIARO should not be mixed with any other vaccine in the same syringe or vial.
Immunosuppressive therapies may decrease the immune response to IXIARO .
About this medicine
11 DESCRIPTIONIXIARO, Japanese Encephalitis Vaccine, Inactivated, Adsorbed is a sterile suspension for intramuscular injection. Each 0.5 mL dose of vaccine contains 6 antigen units of purified, inactivated JEV and approximately 250 mcg of aluminum hydroxide. The appearance of the liquid is a white, opaque, non-uniform suspension which becomes homogeneous upon shaking.IXIARO is a vaccine prepared by propagating JEV strain SA14-14-2 in Vero cells. Multiple viral harvests are pooled, clarified and concentrated. The virus suspension is treated with protamine sulfate to remove contaminating DNA and proteins. The resulting partially purified virus is processed through a sucrose density gradient centrifugation step and fractionated. Each fraction is analyzed for the presence of virus, and fractions with the highest virus activity are pooled to give a purified virus suspension. The purified virus is then inactivated by treatment with formaldehyde. …
Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID e654303b-b7b1-4e5b-a0a1-e999110060bf. Read the full official label on DailyMed.